Aerie's glaucoma treatment gets early FDA approval

(Reuters) - Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.